Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Dipyridamole in Asasantin ER vs Persantin + ASA
NCT02273505Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2000
- Primary completion
- May 2000
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 1, randomised, open-label trial of dipyridamole + aspirin in stroke and Transient Ischemic Attack (TIA) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the plasma concentration-time curve at steady state up to 144 hours and Percentage peak trough fluctuation up to 144 hours. Started Apr 2000; status: completed.
02
Drugs
dipyridamole + aspirin
03
Conditions
strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT02273505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273505.